English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1.4 |
| Open | 1.38 |
| 1-Year Change | N/A |
| Day's Range | 1.36 - 1.43 |
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
BRIEF: For the fiscal year ended 31 December 2021, Marinus Pharmaceuticals Inc revenues increased from $1.7M to $15.3M. Net loss applicable to common stockholders increased 29% to $98.8M. Revenues reflect Federal contract revenue increase from $1.7M to $6.4M. Higher net loss reflects Interest Income decrease of 84% to $80K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.80 to -$2.69.
